0
Two biosimilars—Zimrixby (rituximab-cdxx) and Garzulys (insulin aspart-fsan)—received US Food and Drug Administration (FDA) approval in July 2026, expanding treatment options in oncology, immunolog...
More >- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- FDA approves Zimrixby (rituximab) and Garzulys (insulin aspart) biosimilars
- EMA recommends approval for biosimilar pegfilgrastim Cavoley
- FDA approves first interchangeable ranibizumab biosimilar Ranluspec
- EMA recommends approval for biosimilar Denosumab Ascend and pegfilgrastim Nylaspeg
Research
- Biosimilar interchangeability: a necessary fix, but not a silver bullet
- EULAR 2025 RA guidelines streamlined as biosimilar expansion reshapes treatment sequencing
- Biosimilars uptake in Chile: why does it lag behind?
- Biosimilar aflibercept (AVT06) pre-filled syringe promises safer, faster eye injections
- MORE EDITORIAL SECTIONS
- Search
